These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 33042651)

  • 61. Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors.
    Frąk W; Hajdys J; Radzioch E; Szlagor M; Młynarska E; Rysz J; Franczyk B
    Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509724
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The Ketogenic Effect of SGLT-2 Inhibitors-Beneficial or Harmful?
    Koutentakis M; Kuciński J; Świeczkowski D; Surma S; Filipiak KJ; Gąsecka A
    J Cardiovasc Dev Dis; 2023 Nov; 10(11):. PubMed ID: 37998523
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies.
    Alshnbari AS; Millar SA; O'Sullivan SE; Idris I
    Diabetes Ther; 2020 Sep; 11(9):1947-1963. PubMed ID: 32715425
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Sodium glucose cotransporter-2 inhibitors and heart disease: Current perspectives.
    Mondal S; Pramanik S; Khare VR; Fernandez CJ; Pappachan JM
    World J Cardiol; 2024 May; 16(5):240-259. PubMed ID: 38817648
    [TBL] [Abstract][Full Text] [Related]  

  • 65. SGLT2 inhibition and heart failure-current concepts.
    Custodio JS; Duraes AR; Abreu M; Albuquerque Rocha N; Roever L
    Heart Fail Rev; 2018 May; 23(3):409-418. PubMed ID: 29704192
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The association of sodium-glucose cotransporter 2 inhibitors with cancer: An overview of quantitative systematic reviews.
    Pelletier R; Ng K; Alkabbani W; Labib Y; Mourad N; Gamble JM
    Endocrinol Diabetes Metab; 2020 Jul; 3(3):e00145. PubMed ID: 32704566
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Sodium-glucose Cotransporter 2 Inhibitors: The Impact on Development and Progression of Heart Failure.
    Papademetriou V; Geladari E
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):127-133. PubMed ID: 29618313
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
    Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
    Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Acute Coronary Syndrome: A Modern Cinderella?
    Karakasis P; Fragakis N; Kouskouras K; Karamitsos T; Patoulias D; Rizzo M
    Clin Ther; 2024 Jul; ():. PubMed ID: 38991865
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Heart Failure: An Umbrella Review.
    Roy R; Vinjamuri S; Baskara Salian R; Hafeez N; Meenashi Sundaram D; Patel T; Gudi TR; Vasavada AM
    Cureus; 2023 Jul; 15(7):e42113. PubMed ID: 37602002
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients.
    Tilinca MC; Tiuca RA; Tilea I; Varga A
    J Pers Med; 2021 Nov; 11(12):. PubMed ID: 34945721
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Safety and Efficacy of SGLT2 Inhibitors: A Multiple-Treatment Meta-Analysis of Clinical Decision Indicators.
    Martínez-Vizcaíno V; Díez-Fernández A; Álvarez-Bueno C; Martínez-Alfonso J; Cavero-Redondo I
    J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34205385
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Role of Selective Sodium-Glucose Co-Transporter-2 Inhibitors in Managing Cardio-Renal Complications in Type 2 Diabetes Mellitus: Beyond Glycemic Control.
    Onyali CB; Anim-Koranteng C; Shah HE; Bhawnani N; Ethirajulu A; Alkasabera A; Mostafa JA
    Cureus; 2021 Aug; 13(8):e17452. PubMed ID: 34603858
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A Call for a New Paradigm for Diabetes Care in the Era of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i).
    Kim SH; Chang TI; Mahaffey KW
    Cardiol Ther; 2020 Dec; 9(2):219-225. PubMed ID: 32661684
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacovigilance study for SGLT 2 inhibitors- Safety review of real-world data & randomized clinical trials.
    Bhanushali KB; Asnani HK; Nair A; Ganatra S; Dani SS
    Curr Probl Cardiol; 2024 May; 49(9):102664. PubMed ID: 38789017
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prevalence of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitor Prescribing in Patients with Type 2 Diabetes Mellitus and Reduced Estimated Glomerular Filtration Rate.
    Chonko K; Russo-Alvarez G; Isaacs D; Wang L; Soric A
    Innov Pharm; 2023; 14(2):. PubMed ID: 38025173
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Best practices for safe use of SGLT-2 inhibitors developed from an expert panel Delphi consensus process.
    Pamulapati LG; Rochester-Eyeguokan CD; Pincus KJ
    Am J Health Syst Pharm; 2020 Oct; 77(21):1727-1738. PubMed ID: 32725160
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.
    Herrington WG; Preiss D; Haynes R; von Eynatten M; Staplin N; Hauske SJ; George JT; Green JB; Landray MJ; Baigent C; Wanner C
    Clin Kidney J; 2018 Dec; 11(6):749-761. PubMed ID: 30524708
    [TBL] [Abstract][Full Text] [Related]  

  • 80. SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice.
    Ali A; Bain S; Hicks D; Newland Jones P; Patel DC; Evans M; Fernando K; James J; Milne N; Viljoen A; Wilding J;
    Diabetes Ther; 2019 Oct; 10(5):1595-1622. PubMed ID: 31290126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.